RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients

Clinical Lung Cancer

Volumn 18, Issue 4, 2017, Pages e223-e232

  Sarfaty, Michal ^a,b   Moore, Assaf ^a   Neiman, Victoria ^a,b   Dudnik, Elizabeth ^a   Ilouze, Maya ^a   Gottfried, Maya ^b,c   Katznelson, Rivka ^d,e   Nechushtan, Hovav ^e,f   Sorotsky, Hadas Gantz ^f   Paz, Keren ^g   Katz, Amanda ^g   Saute, Milton ^a,b   Wolner, Mira ^h,i   Moskovitz, Mor ^h   Miller, Vincent ^j   Elvin, Julia ^j   Lipson, Doron ^j   Ali, Siraj ^j   Gutman, Lior Soussan ^k   Dvir, Addie ^k   Gordon, Noa ^a   Peled, Nir ^a,b   more..

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

^d KAPLAN MEDICAL CENTER   (Israel)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g Champions Oncology Inc   (United States)

^h Rambam Health Care Campus   (Israel)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^j FOUNDATION MEDICINE   (United States)

^k TEVA PHARMACEUTICALS   (Israel)

more..

Author keywords

Cabozantinib; Lung cance; PDL 1; Personalized medicine; RET

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; NINTEDANIB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB; VINORELBINE TARTRATE; ANILIDE; ANTINEOPLASTIC AGENT; CCDC62 PROTEIN, HUMAN; KIF5B-RET FUSION PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM DERIVATIVE; PROTEIN RET; PYRIDINE DERIVATIVE; RET PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE STUDY; CCDC6 GENE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; KIF5B GENE; LUNG ADENOCARCINOMA; LUNG METASTASIS; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; ONCOGENE RET; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER STAGING; GENETICS; LUNG TUMOR; METASTASIS; MORTALITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANILIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 85021312138     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.09.003     Document Type: Article

References (19)

1. Kris, M.G., Johnson, B.E., Berry, L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
2. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
3. Takahashi, M., Ritz, J., Cooper, G.M., Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42 (1985), 581–588.
4. Mizukami, T., Shiraishi, K., Shimada, Y., et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. J Thorac Oncol 9 (2014), 622–630.
5. Ju, Y.S., Lee, W.-C., Shin, J.-Y., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22 (2012), 436–445.
6. Elvin, J., Mukhopadhyay, S., Ali, S., et al. Comprehensive genomic profiling (CGP) of 44 RET-fused lung adenocarcinomas (LADCA) with histologic and clinical correlates. Lab Invest, 475A, 2015.
7. Gautschi, O., Zander, T., Keller, F.A., et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 8 (2013), e43–e44.
8. Falchook, G.S., Ordóñez, N.G., Bastida, C.C., et al. Effect of the RET inhibitor vandetanib in a patient with RET fusion–positive metastatic non–small-cell lung cancer. J Clin Oncol 34 (2016), e141–e144.
9. Hidalgo, M., Bruckheimer, E., Rajeshkumar, N., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10 (2011), 1311–1316.
10. Wang, R., Hu, H., Pan, Y., et al. RET fusions define a unique molecular and clinicopathologic subtype of non–small-cell lung cancer. J Clin Oncol 30 (2012), 4352–4359.
11. Oxnard, G.R., Binder, A., Jänne, P.A., New targetable oncogenes in non–small-cell lung cancer. J Clin Oncol 31 (2013), 1097–1104.
12. Lee, J.S., Hirsh, V., Park, K., et al. Vandetanib versus placebo in patients with advanced non–small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30 (2012), 1114–1121.
13. Kodama, T., Tsukaguchi, T., Satoh, Y., et al. Alectinib shows potent antitumor activity against RET-rearranged non–small cell lung cancer. Mol Cancer Ther 13 (2014), 2910–2918.
14. Schoffski, P., Elisei, R., Muller, S., et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol, 30, 2012, 5508.
15. Drilon, A., Wang, L., Hasanovic, A., et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3 (2013), 630–635.
16. Drilon, A.E., Sima, C.S., Somwar, R., et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. J Clin Oncol, 33(suppl), 2015 abstract 8007.
17. Pekar-Zlotin, M., Hirsch, F.R., Soussan-Gutman, L., et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20 (2015), 316–322.
18. Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
19. Lanman, R.B., Mortimer, S.A., Zill, O.A., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One, 10, 2015, e0140712.